Goldman Sachs Group Inc. Invests $33,000 in Relmada Therapeutics, Inc. $RLMD

Goldman Sachs Group Inc. bought a new stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 120,852 shares of the company’s stock, valued at approximately $33,000. Goldman Sachs Group Inc. owned approximately 0.36% of Relmada Therapeutics at the end of the most recent reporting period.

Relmada Therapeutics Trading Up 6.9%

Relmada Therapeutics stock opened at $2.01 on Wednesday. The company has a 50-day moving average price of $1.07 and a 200 day moving average price of $0.70. Relmada Therapeutics, Inc. has a 12-month low of $0.24 and a 12-month high of $3.98. The stock has a market cap of $66.71 million, a P/E ratio of -0.91 and a beta of 0.74.

Relmada Therapeutics (NASDAQ:RLMD) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.05). As a group, analysts forecast that Relmada Therapeutics, Inc. will post -2.73 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Relmada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $1.00.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.